The short answer: Early, company-sponsored analyses suggest that semaglutide and tirzepatide nudge some blood-based “aging clock” readings in a younger direction in people with obesity, heart disease or diabetes. These results are not peer reviewed, none of them tested healthy people, and a better clock reading has not been shown to mean a longer or
Bottom Line On October 28, 2026, Eli Lilly announced topline results from TRANSCEND-T2D-2, a Phase 3 trial of 1,298 adults with type 2 diabetes. After 80 weeks, people taking its investigational drug retatrutide lost about 19.5% (9 mg dose) to 20.9% (12 mg dose) of their body weight and lowered HbA1C by 2.2 percentage points,
A short guide to three stories from this month, explained simply Three stories about GLP-1 medicines got a lot of attention this month. We wrote a full article on each one. This guide gives you the main points in plain language. Each section links to the full article if you want more detail. 1. GLP-1
This Week in Obesity Medicine A Phase 2 trial of petrelintide, a once-weekly amylin drug, showed up to about 10% weight loss at 42 weeks with modest nausea (about 20% vs 6% on placebo). It is not approved, has not been compared directly with GLP-1 drugs, and is in Phase 3. Novo Nordisk’s first real-world
Bottom Line Three independent 2026 surveys agree on the direction, even though they report different numbers: employer coverage of GLP-1 medications for weight loss is retrenching, not expanding, as the drugs’ cost collides with the size of the eligible population. Several large, recognizable employers have dropped or are dropping coverage this year. For patients whose
Bottom Line A large real-world study published in January 2026 found that people with type 2 diabetes on tirzepatide had a lower rate of newly diagnosed dementia over two years than people on semaglutide or on SGLT2 inhibitors, and that semaglutide also outperformed SGLT2 inhibitors. The differences are real and statistically significant, but this is
